Table 1.

Flow-MRD response assessment after treatment of multiple myeloma

		Comment	Patients				Pts. with clinical progression (*1)
(A)	Patients registered/included into the study	Patients included into the study (Inclusion period: 01-03-2012 - 31-03-2014)	136				79
		Patients with only diagnostic BM sample received (until 31-10-2018)		83
		Patients with BM samples for Flow-MRD analysis received (until 31-08-2018)		53			29
(B)	1st flow RA (Flow-MRD analysis FU1)	Patients with BM samples received for 1st Flow-RA		53
		Excluded patients not reaching RS of CR at 1st response assessment			31		13
		Excluded patients (OFF-protocol)			1		1
		Included patients with RS of CR/SCR at 1st response assessment			21		14
		Included with adequate BM sample				15
		Excluded with inadequate BM sample				6
(C)	Longitudinal flow-MRD analysis (FU1-FUX)	Patients with BM samples received for longitudinal analysis		53
		Best reached RS during the patients course: <VGPR				2	1
		Best reached RS during the patients course: VGPR				11	10
		Best reached RS during the patients course: CR				12	5
		Best reached RS during the patients course: sCR				28	13
		Excluded patients (Off-protocol)			2
		Excluded patients not reaching CR over the entire patients course			13
		Excluded with inadequate BM samples (until progression)			4
		Included patients with reached RS CR/SCR over the patients course			34
		Included with ≥ 3 Flow-MRD samples analysed (incl. FU1)				20	7
		Excluded with ≤ 2 Flow-MRD samples analysed (incl. FU1)				14	7

Abbreviations: PR Partial response, VGPR Very good PR, CR Complete response, SCR Stringent CR, Flow-MRD MRD assessment using MFC, RA Response assessment, RS Clinical response category, FU Follow up (FU1 = 1st RA; FUX = subsequent follow ups), Pts Patients. Grey Boxes indicate patients included into the final analysis. (*1): at censoring date